Inactivation of the inhA-encoded fatty acid synthase II (FASII) enoyl- acyl carrier protein reductase induces accumulation of the FASI end products and cell lysis of Mycobacterium smegmatis

Journal of Bacteriology

Volumn 182, Issue 14, 2000, Pages 4059-4067

  Vilchèze, Catherine ^a   Morbidoni, Hector R ^a   Weisbrod, Torin R ^a   Iwamoto, Hiroyuki ^b   Kuo, Mack ^b   Sacchettini, James C ^b   Jacobs Jr , William R ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; FATTY ACID SYNTHASE; ISONIAZID; MYCOLIC ACID; OXIDOREDUCTASE; SATURATED FATTY ACID;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL CELL WALL; CYTOLYSIS; GENE INACTIVATION; GENE MUTATION; MYCOBACTERIUM BOVIS; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL;

ALLELES; ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; BACTERIOLYSIS; DRUG RESISTANCE, MICROBIAL; FATTY ACID SYNTHETASE COMPLEX; FATTY ACIDS; HEAT; ISONIAZID; MYCOBACTERIUM SMEGMATIS; MYCOLIC ACIDS; OXIDOREDUCTASES; PALMITIC ACID;

ACTINOBACTERIA (CLASS); BACTERIA (MICROORGANISMS); CORYNEBACTERINEAE; MYCOBACTERIUM BOVIS BCG; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; PROKARYOTA; UNCULTURED ACTINOMYCETE;

EID: 0038410325     PISSN: 00219193     EISSN: None     Source Type: Journal    
DOI: 10.1128/JB.182.14.4059-4067.2000     Document Type: Article

References (42)

1. Banerjee, A., E. Dubnau, A. Quemard, V. Balasubramanian, K. S. Um, T. Wilson, D. Collins, G. de Lisle, and W. R. Jacobs, Jr. 1994. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263:227-230.
2. Basso, L. A., R. Zheng, J. M. Musser, W. R. Jacobs, Jr., and J. S. Blanchard. 1998. Mechanisms of isoniazid resistance in Mycobacterium tuberculosis: enzymatic characterization of enoyl reductasc mutants identified in isoniazid-resistant clinical isolates. J. Infect. Dis. 178:769-775.
3. Belanger, A. E., and G. F. Hatfull. 1999. Exponential-phase glycogen recycling is essential for growth of Mycobacterium smegmatis. J. Bacteriol. 181: 6670-6678.
4. Bergler, H., G. Hogenauer, and F. Turnowsky. 1992. Sequences of the envM gene and of two mutated alleles in Escherichia coli. J. Gen. Microbiol. 138:2093-2100.
5. Bernstein, J., W. A. Lott, B. A. Steinberg, and H. L. Yale. 1952. Chemotherapy of experimental tuberculosis. Am. Rev. Tuberc. 65:357-374.
6. Bloch, K. 1977. Control mechanisms for fatty acid synthesis in Mycobacterium smegmatis. Adv. Enzymol. Relat. Areas Mol. Biol. 45:1-84.
7. Brindley, D. N., S. Matsumura, and K. Bloch. 1969. Mycobacterium phlei fatty acid synthetase-A bacterial multienzyme complex. Nature 224:666-669.
8. Cohn, D. L., F. Bustreo, and M. C. Raviglione. 1997. Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD global surveillance project. Clin. Infect. Dis. 24:S121-S130.
9. Corey, E. J., and J. W. Suggs. 1975. Pyridinium chlorochromate. An efficient reagent for oxidation of primary and secondary alcohols to carbonyl compounds. Tetrahedron Lett. 31:2647-2650.
10. Dessen, A., A. Quemard. J. S. Blanchard, W. R. Jacobs, Jr., and J. C. Sacchettini. 1995. Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis. Science 267:1638-41.
11. Fox, H. H. 1952. The chemical approach to the control of tuberculosis. Science 116:129-134.
12. Glickman, M. S., J. S. Cox, and W. R. Jacobs, Jr. 2000. A novel mycolic acid cyclopropane synthetase is required for cording, persistence, and virulence of Mycobacterium tuberculosis. Mol. Cell 5:717-727.
13. Heath, R. J., and C. O. Rock. 1995. Enoyl-acyl carrier protein reductase (fabI) plays a determinant role in completing cycles of fatty acid elongation in Escherichia coli. J. Biol. Chem. 270:26538-26542.
14. Heym, B., N. Honore, C. Truffot-Pernot, A. Banerjee, C. Schurra, W. R. Jacobs, Jr., J. D. van Embden, J. H. Grosset, and S. T. Cole. 1994. Implications of multidrug resistance for the future of short-course chemotherapy of tuberculosis: a molecular study. Lancet 344:293-298.
15. Johnsson, K., D. S. King, and P. G. Schultz. 1995. Studies on the mechanisms of action of isoniazid and ethionamide in the chemotherapy of tuberculosis. J. Am. Chem. Soc. 117:5009-5010.
16. Kikuchi, S., D. L. Rainwater, and P. E. Kolattukudy. 1992. Purification and characterization of an unusually large fatty acid synthase from Mycobacterium tuberculosis var. bovis BCG. Arch. Biochem. Biophys. 295:318-326.
17. Klann, A. G., A. E. Belanger, A. Abanes-De Mello, J. Y. Lee, and G. F. Hatfull. 1998. Characterization of the dnaG locus in Mycobacterium smegmatis reveals linkage of DNA replication and cell division. J. Bacteriol. 180:65-72.
18. Kremer, L., J. D. Douglas, A. R. Baulard, C. Morehouse, M. R. Guy, D. Alland, L. G. Dover, J. H. Lakey, W. R. Jacobs, Jr., P. J. Brennan, D. E. Minnikin, and G. S. Besra. 2000. Thiolactomycin and related-analogues as novel anti-mycobacterial agents targeting KasA and KasB condensing enzymes in Mycobacterium tuberculosis. J. Biol. Chem. 275:16857-16864.
19. Lee, A. S., I. H. Lim, L. L. Tang, A. Telenti, and S. Y. Wong. 1999. Contribution of kasA analysis to detection of isoniazid-resistant Mycobacterium tuberculosis in Singapore. Antimicrob. Agents Chemother. 43:2087-2089.
20. Lei, B., C.-J. Wei, and S.-C. Tu. 2000. Action mechanism of antitubercular isoniazid. J. Biol. Chem. 275:2520-2526.
21. Marrakchi, H., G. Lanéelle, and A. Quémard. 2000. InhA, a target of the antituberculous drug isoniazid, is involved in a mycobacterial fatty acid elongation system, FAS-II. Microbiology 146:289-296.
22. Mdluli, K., D. R. Sherman, M. J. Hickey, B. N. Kreiswirth, S. Morris, C. K. Stover, and C. E. Barry 3rd. 1996. Biochemical and genetic data suggest that InhA is not the primary target for activated isoniazid in Mycobacterium tuberculosis. J. Infect. Dis. 174:1085-1090.
23. Mdluli, K., R. A. Slayden, Y. Zhu, S. Ramaswamy, X. Pan, D. Mead, D. D. Crane, S. V. Musser, and C. E. Barry 3rd. 1998. Inhibition of a Mycobacterium tuberculosis β-ketoacyl ACP synthase by isoniazid. Science 280:1607-1610.
24. Mehta, A., A. M. Oeser, and M. G. Carlson. 1998. Rapid quantitation of free fatty acids in human plasma by high-performance liquid chromatography. J. Chromatogr. B. 719:9-23.
25. Miesel, L., T. R. Weisbrod, J. A. Marcinkeviciene, R. Bittman, and W. R. Jacobs, Jr. 1998. NADH dehydrogenase defects confer isoniazid resistance and conditional lethality in Mycobacterium smegmatis. J. Bacteriol. 180:2459-2467.
26. Monteagudo, E. S., G. Burton, and E. G. Gros. 1990. Synthesis of 24-methylene [24-C-14]-cholesterol and 24-methylidene [7-H-13] cholesterol. Helv. Chim. Acta 73:2097-2100.
27. Peterson, D. O., and K. Bloch. 1977. Mycobacterium smegmatis fatty acid synthetase. Long chain transacylase chain length specificity. J. Biol. Chem. 252:5735-5739.
28. Piatek, A. S., A. Telenti, M. R. Murray, H. El-Hajj, W. R. Jacobs, Jr., F. R. Kramer, and D. Alland. 2000. Genotypic analysis of Mycobacterium tuberculosis in two distinct populations using molecular beacons: implications for rapid susceptibility testing. Antimicrob. Agents Chemother. 44:103-110.
29. Quemard, A., J. C. Sacchettini, A. Dessen, C. Vilcheze, R. Bittman, W. R. Jacobs, Jr., and J. S. Blanchard. 1995. Enzymatic characterization of the target for isoniazid in Mycobacterium tuberculosis. Biochemistry 34:8235-8241.
30. Ristow, M., M. Mohlig, M. Rifai, H. Schatz, K. Feldmann, and A. Pfeiffer. 1995. New isoniazid/ethionamide resistance gene mutation and screening for multidrug-resistant Mycobacterium tuberculosis strains. Lancet 346:502-503.
31. Rozwarski, D. A., G. A. Grant, D. H. R. Barton, W. R. Jacobs, Jr., and J. C. Sacchettini. 1998. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science 279:98-102.
32. Skold, O. 1976. R-factor-mediated resistance to sulfonamides by a plasmid-borne, drug-resistant dihydropteroate synthase. Antimicrob. Agents Chemother. 9:49-54.
33. Snapper, S. B., R. E. Melton, S. Mustafa, T. Kieser, and W. R. Jacobs, Jr. 1990. Isolation and characterization of efficient plasmid transformation mutants of Mycobacterium smegmatis. Mol. Microbiol. 4:1911-1919.
34. Takayama, K., L. Wang, and H. L. David. 1972. Effect of isoniazid on the in vivo mycolic acid synthesis, cell growth, and viability of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2:29-35.
35. Takayama, K., L. Wang, and R. S. Merkal. 1973. Scanning electron microscopy of the H37Ra strain of Mycobacterium tuberculosis exposed to isoniazid. Antimicrob. Agents Chemother. 4:62-65.
36. Takayama, K., H. K. Schnoes, E. L. Armstrong, and R. W. Boyle. 1975. Site of inhibitory action of isoniazid in the synthesis of mycolic acids in Mycobacterium tuberculosis. J. Lipid Res. 16:308-317.
37. Telenti, A., N. Honore, C. Bernasconi, J. March, A. Ortega, B. Heym, H. E. Takiff, and S. T. Cole. 1997. Genotypic assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: a blind study at reference laboratory level. J. Clin. Microbiol. 35:719-723.
38. Wilming, M., and K. Johnsson. 1999. Spontaneous formation of the bioactive form of the tuberculosis drug isoniazid. Angew. Chem. Int. Ed. 38:2588-2590.
39. Wilson, M., J. DeRisi, H. H. Kristensen, P. Imboden, S. Rane, P. O. Brown, and G. K. Schoolnik. 1999. Exploring drug-induced alterations in gene expression in Mycobacterium tuberculosis by microarray hybridization. Proc. Natl. Acad. Sci. USA 96:12833-12838.
40. Winder, F. G., and P. B. Collins. 1970. Inhibition by isoniazid of synthesis of mycolic acids in Mycobacterium tuberculosis. J. Gen. Microbiol. 63:41-48.
41. Zabinski, R. F., and J. S. Blanchard. 1997. The requirement for manganese and oxygen in the isoniazid-dependent inactivation of Mycobacterium tuberculosis enoyl reductase. J. Am. Chem. Soc. 119:2331-2332.
42. Zhang, Y., B. Heym, B. Allen, D. Young, and S. Cole. 1992. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 358:591-593.